9 results
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
against Amgen based on Amgen’s commercialization of an anti-sclerostin antibody, Evenity®, for the treatment of osteoporosis in postmenopausal women
F-1/A
MREO
Mereo Biopharma Group Plc
12 Mar 20
Registration statement (foreign) (amended)
5:15pm
Enrollment
Target
Start
Phase 1
Healthy Volunteers (postmenopausal women)
Phase
2b
OI
(adult)
Phase 3
OI
(pediatrics)
Phase
3 ready
in EU
Phase 2 …
Hypophosphatasia
Phase 2
Women with Low Bone Mineral Density
Phase 2
OI
Phase 1 and Phase 2 Clinical Trials in Other Indications
Novartis performed a Phase 1
F-1/A
MREO
Mereo Biopharma Group Plc
6 Mar 20
Registration statement (foreign) (amended)
5:32pm
Volunteers (postmenopausal women)
Phase
2b
OI
(adult)
Phase 3
OI
(pediatrics)
Phase
3 ready
in EU
Phase 2
Hypophosphatasia
Phase 2
Women with Low Bone Mineral … in a total of 44 postmenopausal women with low bone mineral density, in which 36 subjects were treated with setrusumab. The trial had four arms
20-F
2018 FY
MREO
Mereo Biopharma Group Plc
29 Apr 19
Annual report (foreign)
4:59pm
Phase
Population
Enrollment
Phase
Population
Planned
Enrollment
Target Start
Phase 1
Healthy Volunteers (postmenopausal women)
Phase 2b
OI (adult)
Phase … 3
OI (pediatrics)
Phase 3
ready in EU
Phase 2
Hypophosphatasia
Phase 2
Women with Low Bone Mineral Density
Phase 2
OI
Phase 1 and Phase 2 Clinical
425
97bfb x0rqr
15 Feb 19
Business combination disclosure
6:50am
425
s00jg31kkd86
12 Feb 19
Business combination disclosure
12:00am
425
56n1td am28
7 Jan 19
Business combination disclosure
11:50am
425
f72vi
11 Dec 18
Business combination disclosure
1:16pm
- Prev
- 1
- Next